Clinical Trial Search

Phase 3 N=657 Efficacy, Safety, and Tolerability of NVA237 Compared to Tiotropium in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

Primary: Trough Forced Expiratory Volume in 1 Second (FEV1) After 12 Weeks of Treatment (Non-inferiority Analysis) — 1.405; 1.405 Liters

Novartis Pharmaceuticals Results Apr 2014 3.7% serious AE View details

Phase 2 N=34 Safety and Efficacy of L-NAME and Midodrine to Increase MAP

Orthostatic Hypotension · Spinal Cord Injury

Primary: Blood Pressure — 120; 112; 117; 109 mmHg

US Department of Veterans Affairs Results Apr 2014 0.0% serious AE View details

Phase 4 N=202 A Study Evaluating Dosing Regimens for Treatment With Intravitreal Ranibizumab Injections in Subjects With Macular Edema Following Retinal Vein Occlusion

Macular Edema

Primary: Trend of Change From Baseline in the Best Corrected Visual Acuity (BCVA) Scores From Month 7 to Month 15 — 17.5; 19.7; 18.7; 21.0 Letters — p=0.5091

Genentech, Inc. Results Apr 2014 18.3% serious AE View details

Phase 2 N=185 A Long-Term Extension Trial From Late Phase II of SPM 962 in Patients With Restless Legs Syndrome

Idiopathic Restless Legs Syndrome

Primary: The Incidence and Severity of Adverse Events (AEs), Vital Signs, and Laboratory Parameters — 175; 139; 5; 1 participants

Otsuka Pharmaceutical Co., Ltd. Results Apr 2014 2.7% serious AE View details

Phase 4 N=180 A Study of Sodium Carboxymethylcellulose for Post Cataract Surgery Dry Eye Symptoms

Dry Eye Syndromes · Cataract

Primary: Tear Break-Up Time (TBUT) in the Study Eye — 8.5; 6.6 Seconds

Allergan Results Apr 2014 0.0% serious AE View details

Phase 4 N=51 Study of Raisins Versus Alternative Snacks in Patients With Type 2 Diabetes Mellitus

Diabetes Mellitus

Primary: Postprandial Glucose Levels — -6; 17 percent — p==0.024

Louisville Metabolic and Atherosclerosis… Results Apr 2014 2.2% serious AE View details

Phase 3 N=59 Clinical Trial of CNS-targeted HAART (CIT2)

HIV Infections

Primary: Neuropsychological Performance Change — -0.27; -0.17 units on a scale

University of California, San Diego Results Apr 2014 3.4% serious AE View details

N/A N=54 A Study of Treatment Preference During Cheek Contouring Comparing Restylane® SubQ With and Without the Addition of Lidocaine Hydrochloride

Facial Tissue Augmentation

Primary: Percentage of Subjects Who Assessed Treatment With Restylane SubQ Lidocaine as Least Painful. — 100 percentage of participants

Galderma R&D Results Apr 2014 2.5% serious AE View details

Phase 3 N=425 Trial to Demonstrate the Efficacy and Safety of Conversion to Lacosamide Monotherapy for Partial-onset Seizures

Epilepsy

Primary: Percentage of Subjects (Using Kaplan-Meier) Who Are Identified As Meeting At Least 1 Pre-defined Exit Criteria By Day 112 Relative To The Start of Withdrawal of…

UCB BIOSCIENCES, Inc. Results Apr 2014 5.9% serious AE View details

Phase 4 N=665 Combining Medications to Enhance Depression Outcomes

Major Depressive Disorder

Primary: Quick Inventory of Depressive Symptoms — 46.6; 41.8; 46.0 percentage of participants

National Institute of Mental Health (NIMH) Results Apr 2014 6.2% serious AE View details

N/A N=5,745 Effectiveness and Safety of Adalimumab in Rheumatoid Arthritis Patients in Routine Clinical Practice

Rheumatoid Arthritis

Primary: Change From Baseline in Disease Activity Score (DAS) 28 — -1.6; -1.8; -2.0; -2.1 units on a scale

AbbVie (prior sponsor, Abbott) Results Apr 2014 2.8% serious AE View details

Phase 1 N=21 Safety Study of Repeated Dosing of a Cytotoxic Lymphocytes (CTL) Based Prostate Cancer Therapy

Hormone-refractory Prostate Cancer

Primary: Adverse Events — 67; 8; 9; 0 Events

CytoVac A/S Results Apr 2014 33.3% serious AE View details

Phase 3 N=393 An Efficacy, Safety and Tolerability Study of TMC435 in Genotype 1 Hepatitis C-infected Patients Who Relapsed After Previous Therapy

Hepatitis C

Primary: The Percentage of Participants Achieving a Sustained Virologic Response 12 Weeks After the Planned End of Treatment (SVR12) — 79.2; 36.1 Percentage of participants…

Janssen R&D Ireland Results Apr 2014 6.4% serious AE View details

Phase 3 N=395 A Study to Evaluate the Effectiveness and Safety of a Fixed Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients With High Blood Pressure Who do Not Achieve Target Blood Pressure Following Treatment With Azilsartan Medoxomil Alone

Essential Hypertension

Primary: Change From Baseline to Week 8 in Trough, Sitting, Clinic Systolic Blood Pressure — 150.7; 149.8; 149.8; -6.4 mm Hg — p=<0.001

Takeda Results Apr 2014 0.5% serious AE View details

N/A N=30 Effect of Managing Problematic Eating Behaviours With Dietary Management on Chronic Disease Self-management

Hypertension · Type 2 Diabetes

Primary: The Change in EEQ (Emotional Eater Questionnaire) Score is the Primary Outcome Measure in This Study. — -1.7; -3.2 Scores on a scale

University of Toronto Practice Based Research… Results Apr 2014 0.0% serious AE View details